Management of Adult Onset Familial Hemophagocytic Lymphohistiocytosis (FHL): A Dilemma
Journal Title: Haematology International Journal - Year 2018, Vol 2, Issue 2
Abstract
Background: Perforin gene (PRF1) mutations cause the familial form of hemophagocytic lymphohistiocytosis (HLH). Case presentation: Here, we report a 36-year-old male with familial HLH, who was initially thought to be secondary HLH and was treated accordingly. It is only after a relapse, patient was screened for FHL which revealed perforin deficiency due to previously reported c.694C>T (p.Arg232Cys) mutation. However, till the decision of HSCT could be made, the patient succumbed to the disease. Conclusion: Often, HLH in adults is usually attributed to an infectious etiology without a full genetic workup being undertaken. This not only causes delay in diagnosis, but also adversely affects the management of the patient. It is seen that though in few patients, the onset of HLH is delayed; the outcome remains poor as in classical severe perforin deficiency patients. Hence, it is essential to screen all the patients fitting into HLH criteria irrespective of the age of onset and identify the underlying genetic defect. Even patients with adult onset FHL have a fatal outcome unless treated with HSCT and hence prompt initiation of immunosuppressive and early HSCT is essential for the long term survival.
Authors and Affiliations
Manisha Madkaikar
Keywords
Related Articles
- EP ID EP335840
- DOI -
- Views 90
- Downloads 0
Hemochromatosis Gene Mutation and Erythrocytosis
In a patient group presenting with either increased Hgb level or high RBC count HFE gene mutations occured in two-third of the patients. The explanation for this phenomenon is still missing. These patients had normal ery...
Peripheral T Cell Lymphoma with Follicular Helper Phenotype, Case Report and Literature Review
T-cell lymphomas are a heterogeneous group of lymphoid neoplasms, with a broad classification; in which the peripheral T-cell lymphoma not otherwise specified, is the most frequently diagnosed subtype, demonstrating the...
Surface and Interacellular Targets of Acute Myeloid Leukemia Therapy Detectable at Leukemic Stem Cell level
For over 50 years investigators have considered a malignant stem cell as the potential origin of and a key therapeutic target for acute myeloid leukaemia (AML) and other forms of cancer [1]. Leukaemic stem cells (LSCs) h...
Cost-Effectiveness of Idelalisib-Rituximab for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia
1.1. Background: A significant survival prolongation was recently reported by adding idelalisib to rituximab (IR) compared with rituximab (R) in the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL). No...
Rare Oral Mucosal Manifestations of Hydroxyurea Therapy in Chronic Myeloid Leukemia
Chronic myeloid leukemia (CML), is myeloproliferative neoplasm, that accounts for 15-20% of all leukemia’s in adults, resulting from reciprocal translocation between the long arms of chromosomes 9 and 22(Philadelphia chr...